Veracyte (VCYT) Misses Q2 EPS by 4c

Veracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.35), $0.04 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $11.9 million versus the consensus estimate of $12.23 million.

Veracyte reaffirmed FY2015 guidance.

"We continue to see strong growth of Afirma across both community-based physicians and institutions, driven by increased insurance coverage and contracts and by the deepening recognition among providers and payers of our solution's proven value in reducing unnecessary surgeries and healthcare costs. This increased adoption puts us on track to achieve our annual growth goals," said Bonnie H. Anderson, Veracyte's president and chief executive officer. "In our second clinical indication, pulmonology, we are pleased with our progress in securing early adopters for our Percepta™ Bronchial Genomic Classifier. This allows us to build the clinical evidence to secure coverage for this genomic test, which is designed to reduce ambiguity in lung cancer diagnosis."

For earnings history and earnings-related data on Veracyte (VCYT) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• AppFolio (APPF) Tops Q1 EPS by 17c
• MidWestOne Financial Group, Inc. (MOFG) Misses Q1 EPS by 15c